Valuation : Sernova Biotherapeutics Inc

Market Cap 41.54M 30.08M 25.87M 24.33M 22.21M 2.84B 41.68M 288M 112M 1.46B 113M 110M 4.64B P/E 2026 *
-3.67x
P/E 2027 * -2.75x
Enterprise Value 41.54M 30.08M 25.87M 24.33M 22.21M 2.84B 41.68M 288M 112M 1.46B 113M 110M 4.64B EV / Sales 2026 *
-
EV / Sales 2027 * 8.31x
Free-Float
89.49%
Yield 2026 *
-
Yield 2027 * -
1 day-4.35%
1 month-4.35%
3 months-26.67%
6 months-31.25%
Current year-15.38%
1 week 0.11
Extreme 0.11
0.12
1 month 0.1
Extreme 0.1
0.12
Current year 0.1
Extreme 0.1
0.2
1 year 0.1
Extreme 0.1
0.2
3 years 0.1
Extreme 0.1
0.83
5 years 0.1
Extreme 0.1
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 2024-08-11
Director of Finance/CFO 60 2024-10-10
Investor Relations Contact - 2024-10-10
Director TitleAgeSince
Director/Board Member 60 2012-04-18
Director/Board Member - 2023-04-23
Director/Board Member - 2024-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/3/26 SellCompany -115,000 0.0305%
5/22/26 Option

Chairman

228,912 0.0658%
5/22/26 Option

Director

260,000 0.0748%
Change 5-day change 1-year change 3-year change Capi.($)
-4.35%0.00%-43.59%-87.21% 30.03M
-1.58%-6.38%-22.73%+4.88% 116B
0.00%+0.14%-24.86%+0.24% 12.1B
-1.60%-1.16%+88.92%+135.37% 10.46B
-0.58%+0.16%-51.29%-70.25% 4.2B
-0.97%-2.53%-24.95%+37.21% 2.48B
-0.54%-3.54% - - 1.94B
+1.51%+0.14%-27.04%-72.92% 1.82B
-0.31%-2.35%-18.72%-24.75% 1.57B
Average -0.94%-1.73%-15.53%-9.68% 16.76B
Weighted average by Cap. -1.35%-6.59%-15.92%+10.81%

Financials

2026 *2027 *
Net sales - 5M 3.62M 3.11M 2.93M 2.67M 342M 5.02M 34.72M 13.42M 175M 13.6M 13.3M 559M
Net income -12.83M -9.29M -7.99M -7.51M -6.86M -878M -12.87M -89.08M -34.43M -450M -34.88M -34.12M -1.43B -19.77M -14.32M -12.31M -11.58M -10.57M -1.35B -19.84M -137M -53.08M -693M -53.77M -52.59M -2.21B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
26-09-04 $0.1100 -4.35% 65,264
26-09-03 $0.1150 0.00% 37,000
26-09-02 $0.1150 +4.55% 5,000
26-09-01 $0.1100 0.00% 112,500
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1100CAD
Average target price
0.4500CAD
Spread / Average Target
+309.09%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!